Abstract
TO THE EDITOR—Ray and colleagues recently demonstrated hepatitis C virus (HCV) glycoprotein-specific neutralizing responses against homologous HCV-1 and the closely related genotype 1a HCV strain H77 [1]. Using well-characterized pseudoparticle (HCVpp) and cell culture replicating virus systems (HCVcc) [2], we set out to further investigate the breadth of the neutralizing responses elicited by vaccination. We tested serum samples from 8 of the volunteers reported in the study by Ray et al [1], selecting representative samples that had low, intermediate, and high anti-E1E2 antibody titers as measured by enzyme immunoassay (Novartis Vaccines and Diagnostics, Emeryville, CA).